Recent docking studies have optimized Ang-2 analogues for tighter LRP1 binding [121,122,123]; an Ang-2–drug conjugate crossed the BBB and accumulated in brain tumors in clinical trials (ANG1005 for glioma). This evidence concerns the gene LRP1 and central nervous system cancer.